US 10696693
Fused imidazole derivatives as TGF-beta inhibitors
granted A61KA61K31/416A61K31/4188
Quick answer
US patent 10696693 (Fused imidazole derivatives as TGF-beta inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K31/416, A61K31/4188, A61K31/428, A61K31/4365